Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

NCT02583893 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: Sirolimus
DRUG: Mitoxantrone
DRUG: Etoposide
DRUG: Cytarabine

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University